Treatment-related myelodysplastic syndrome: Molecular characteristics and therapy

Current Opinion in Hematology

Volumn 18, Issue 2, 2011, Pages 77-82

  Bhatia, Ravi ^a,b   Deeg, H Joachim ^a,b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

genetic instability; genetic polymorphisms; hematopoietic cell transplantation; treatment related myelodysplastic syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; CYTOTOXIC AGENT; FLUDARABINE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; PROTEIN MDM2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME DELETION; CHROMOSOME LOSS; DRUG INDUCED DISEASE; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC SUSCEPTIBILITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYELODYSPLASTIC SYNDROME; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; WHOLE BODY RADIATION;

CHROMOSOME ABERRATIONS; DRUG THERAPY; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELODYSPLASTIC SYNDROMES; TRANSPLANTATION, HOMOLOGOUS;

EID: 79952041645     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328343997a     Document Type: Article

References (23)

1. Vardiman JW. The World Health Organization (WHO) classification of tumors • of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact 2010; 184:16-20.
2. Smith SM, Le Beau MM, HuoD, etal. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102:43-52. (Pubitemid 36759634)
3. Qian Z, Joslin JM, Tennant TR, et al. Cytogenetic and genetic pathways in • therapy-related acute myeloid leukemia. Chem Biol Interact 2010; 184:50-57.
4. Graubert TA, Payton MA, Shao J, et al. Integrated genomic analysis •• implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS One 2009; 4: e4583.
5. Lane SW, Sykes SM, Al-Shahrour F, et al. The Apc(min) mouse has altered •hematopoietic stem cell function and provides a model for MPD/MDS. Blood 2010; 115:3489-3497.
6. Wong JC, Zhang Y, LieuwKH, etal. Use of chromosome engineering to model •• a segmental deletion of chromosome band 7q22 found in myeloid malig nancies. Blood 2010; 115:4524-4532.
7. Bolufer P, Collado M, Barragan E, et al. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol 2007; 136:590-596. (Pubitemid 46148195)
8. Ellis NA, Huo D, Yildiz O, etal. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008; 112:741-749.
9. Knight JA, Skol AD,Shinde A, etal. Genome-wide association study to identify •novel loci associated with therapy-related myeloid leukemia susceptibility. Blood 2009; 113:5575-5582.
10. Funk RK, Maxwell TJ, Izumi M, et al. Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice. Blood 2008; 112:1434-1442.
11. Guillem V, Tormo M. Influence of DNA damage and repair upon the risk of treatment related leukemia. Leuk Lymphoma 2008; 49:204-217. (Pubitemid 351193913)
12. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001; 19:1405-1413. (Pubitemid 32202547)
13. O'Sullivan RJ, Karlseder J. Telomeres: protecting chromosomes against genome instability. Nat Rev Mol Cell Biol 2010; 11:171-181.
14. Chakraborty S, Sun CL, Francisco L, et al. Accelerated telomere shortening •precedes development of therapy-related myelodysplasia or acute myelogen ous leukemia after autologous transplantation for lymphoma. J Clin Oncol 2009; 27:791-798.
15. Scheinberg P, Cooper JN, Sloand EM, et al. Association of telomere length of •peripheral blood leukocytes with hematopoietic relapse, malignant transfor mation, and survival in severe aplastic anemia. JAMA 2010; 304:1358-1364.
16. Gruschkus SK, Lairson D, Dunn JK, et al. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma. Cancer 2010; 116:5279-5289.
17. Cachaco AS, CarvalhoT, Santos AC, etal. TNF-alpha regulates the effects of • irradiation in the mouse bone marrow microenvironment. PLoS One 2010; 5:e8980.
18. Stirewalt DL, Mhyre AJ, Marcondes M, et al. Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? Br J Haematol 2008; 140:444-453.
19. Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction • induces myelodysplasia and secondary leukaemia. Nature 2010; 464:852-857.
20. Li L, Li M, Sun C-L, etal. Gene expression changes in CD34+ cells precede • development of therapy-related leukemia (t-MDS) after autologous hemato poietic cell transplantation (aHCT) for Hodgkin (HL) or non-Hodgkin lympho ma (NHL). Blood 2009; 114:677.
21. Chang C, Storer BE, Scott BL, etal. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007; 110:1379-1387. (Pubitemid 47281440)
22. Litzow MR, Tarima S, Perez WS, et al. Allogeneic transplantation for therapy-•• related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115:1850-1857.
23. Kroger N, ZabelinaT, van Biezen A, etal. Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. Haematologica 2010 [Epub ahead of print].